⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 3, 2019The Journal of Clinical Endocrinology & MetabolismOpen Access

Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors

View Full Paper

Ask AI

Bookmark

Share

Abstract

DA therapy poses a high, previously underestimated risk of ICDs, especially in the form of hypersexuality in eugonadal men.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sousa et al. (2019) studied this question.

synapsesocial.com/papers/69dd5cbc4917c2595e101363 https://doi.org/10.1210/clinem/dgz076

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomasCross-Sectional Study · 2018 · 87 citations
2Guidelines of the Pituitary Society for the diagnosis and management of prolactinomasCohort Study · 2006 · 830 citations
3High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liege, BelgiumCross-Sectional Study · 2006 · 1,025 citations
460 YEARS OF NEUROENDOCRINOLOGY: The hypothalamo-prolactin axisReview · 2015 · 348 citations
5Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatristOriginal Research · 2018 · 23 citations